Moderna, Inc. vs Abbvie Inc.
MRNA vs ABBV — side-by-side comparison from reported financials. MRNA leads 4, ABBV leads 7 of 11 comparable metrics.
Moderna, Inc.
MRNA · Healthcare
$225.15+14.29%Strong
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | MRNA | ABBV |
|---|---|---|
| Price | $225.15 | $276.43 |
| Market cap | $89.9B | $488B |
| Revenue (TTM) | $2.23B | $64.4B |
| Revenue growth | -53.4% | +1.8% |
| Net margin | -141.4% | 9.8% |
| Free cash flow | -$1.24B | $18.2B |
| Net cash (debt) | $5.21B | ($56.2B) |
| 1-year price return | +717.8% | +19.8% |
| P/E | 3.9 | 77.4 |
| P/E vs own history (cheap-side %) | 10% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | -39% | 96% |
| Altman Z-score | 13.40 | 2.33 |
| CV checks passed | 6 of 10 | 9 of 10 |
| Employees | 4,700 | 57,000 |
Full résumé-style profiles: MRNA CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.